Images List Premium Download Classic

Cathepsin

Cathepsin-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Protease inhibitors
June 15, 2017 - N°20170166538

Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases:
Hydroxystatin derivatives for the treatment of arthrosis
Merck Patent Gmbh
March 23, 2017 - N°20170081361

The present invention relates to compounds of the formula (i) and in particular to medicaments comprising at least one compound of the formula (i) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin d is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic ...
Novel substituted spirocycles
Merck Patent Gmbh
March 16, 2017 - N°20170073352

Wherein a and cy have one of the meanings as indicated in the specification and their use as inhibitors of cathepsin c, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase i activity, e. G. Respiratory diseases.
Cathepsin Patent Pack
Download + patent application PDFs
Cathepsin Patent Applications
Download + Cathepsin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cathepsin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods for detection and treatment of neurodegenerative diseases
Merck Patent Gmbh
February 16, 2017 - N°20170044590

Provided herein are methods for detecting an increased probability or risk of neurodegeneration in a subject. In some embodiments the method comprises assaying a sample from the subject for lysozyme and/or cathepsin s and detecting the lysozyme and/or cathepsin s from the sample, wherein an increased lysozyme and/or cathepsin s compared to levels in a control subject ...
Novel assay for early detection of a disease using a magnetic nanoparticle biosensor
Alfaisal University
February 09, 2017 - N°20170037450

A multiplex hand-held diagnostic biosensor, using two inflammatory salivary biomarkers, human neutrophil elastase (hne) and cathepsin-g, was constructed made to potentially detect periodontitis at an early stage is described. The use of magnetic nanoparticle biosensor method used as a device was based on the measurement of proteolytic activity using specific proteases probes. The magnetic nanoparticle biosensor device is capable of ...
Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
Mesoblast International Sàrl
December 29, 2016 - N°20160375100

The present invention features mutant stromal cell derived factor-1 (sdf-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase iv (dppiv), matrix metalloproteinase-2 (mmp-2), matrix metalloproteinase-9 (mmp-9), leukocyte elastase, cathepsin g, carboxypeptidase m, and carboxypeptidase n, but which retain chemoattractant activity.
Cathepsin Patent Pack
Download + patent application PDFs
Cathepsin Patent Applications
Download + Cathepsin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cathepsin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors
Mesoblast International Sàrl
December 15, 2016 - N°20160361295

Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.
Cathepsin cysteine protease inhibitors
Merck Sharp & Dohme Corp.
December 08, 2016 - N°20160355502

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins k, l, s and b. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity
Merck Sharp & Dohme Corp.
November 17, 2016 - N°20160333051

Wherein z is a chain of 11 α-amino acid residues which, depending on their positions in the chain (counted starting from the n-terminal amino acid) are gly, or pro, or pro(4nhcophe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property ...
Cathepsin cysteine protease inhibitors
Merck Sharp & Dohme Corp.
August 25, 2016 - N°20160244417

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins k, l, s and b. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Merck Sharp & Dohme Corp.
August 18, 2016 - N°20160237060

Wherein ht, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the ...
Aminostatin derivatives for the treatment of arthrosis
Merck Patent Gmbh
August 11, 2016 - N°20160228493

The present invention relates to compounds of the formula (i) and in particular medicaments comprising at least one compound of the formula (i) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin d is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage ...
Nitrogen-containing bicyclic aromatic heterocyclic compound
Astellas Pharma Inc.
August 11, 2016 - N°20160228442

On the basis of a cathepsin s inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided. It was found that a nitrogen-containing bicyclic heterocyclic compound has an excellent cathepsin s inhibitory effect, thereby completing the invention. The compound of ...
Cathepsin Patent Pack
Download + patent application PDFs
Cathepsin Patent Applications
Download + Cathepsin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cathepsin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Formulations for cathepsin k inhibitors with vitamin d
Merck Sharp & Dohme Corp.
June 16, 2016 - N°20160166529

The instant invention relates to pharmaceutical compositions comprising cathespin k inhibitors and vitamin d. Also disclosed are processes for making said pharmaceutical compositions,
Hydroxy-ethylene derivatives for the treatment of arthrosis
Merck Patent Gmbh
May 26, 2016 - N°20160145297

The present invention relates to compounds of the formula i and in particular medicaments comprising at least one compound of the formula i for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin d is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage ...
Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (...
University Of North Carolina At Pembroke
May 19, 2016 - N°20160136229

The present invention provides methods for treating a subject afflicted with i) mild cognitive impairment (mci), ii) early dementia, iii) early α-synucleinopathy, iv) traumatic brain injury, v) cardiomyopathy, vi) eye disease, or vii) skin damage, comprising administering to the subject at least one compound that increases the level of active cathepsin b in cells of the subject, or ...
Compositions and methods for inhibiting bacterial and viral pathogens
Keck Graduate Institute Of Applied Life Sciences
April 28, 2016 - N°20160113920

Compositions and methods including amodiaquine (aq) or n-desethy amodiaquine (deaq) are provided for treating, inhibiting, or preventing cathepsin b dependent pathogens and toxins in a host cell or infected subject. Compositions and methods also include aq or deaq in combination with an antibiotic for more effective clearance of the pathogen and/or toxins.
Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity
National Research Council Of Canada
March 24, 2016 - N°20160082083

Insulin-like growth factor binding proteins (igfbps) and variants thereof, including igfbp-1, igfbp-2, igfbp-3, igfbp-4, igfbp-5, igfbp-8 and the c-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin b activity.
Methods for treating pulmonary emphysema using substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of ...
National Research Council Of Canada
March 24, 2016 - N°20160081982

And their use as inhibitors of cathepsin c, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase i activity, e. G. Respiratory diseases.
Novel substituted spirocycles
National Research Council Of Canada
March 17, 2016 - N°20160075704

Wherein a and cy have one of the meanings as indicated in the specification and their use as inhibitors of cathepsin c, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase i activity, e. G. Respiratory diseases.
Protease inhibitors
National Research Council Of Canada
March 10, 2016 - N°20160068539

Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.
Loading